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The left-handedparallelbhelix (LbH) fold has recently
receivedattentionasapossible structure for theprion
protein (PrP) in its misfolded state. In light of this
interest, we have developed an experimental system
to examine the structural requirements of the LbH
fold, using a known LbH protein, UDP-N-acetylglu-
cosamine acyltransferase (LpxA), from E. coli. We
showed that the b helix can tolerate nonhydrophobic
residues at interior positions and prolines were
important, but not critical, in folding of the b helix.
Using our structural studies of the LbH, we threaded
the sequence of the amyloidogenic fragment of the
prion protein (residues 104–143) onto the structure
of LpxA. Based on the threading result, we con-
structed the recombinant PrP-LpxA and tested its
functional activity in an E. coli antibiotic sensitivity
assay. The results of these experiments suggest
that the amyloidogenic PrP fragment may fold into
a b helix in the context of a larger b-helical structure.
INTRODUCTION
The parallel b helix is a repetitive protein fold where the repeating
unit is a b-helical coil formed by segments ofb strands (Choi et al.,
2008; Iengar et al., 2006; Jenkins and Pickersgill, 2001). Each
rung of the canonical b helix consists of two to three b strands in-
terrupted by turn or loop regions (Iengar et al., 2006; Kajava and
Steven, 2006; Simkovsky and King, 2006). The b-helical rungs
are aligned to form a cross-b structure, such that elongated
b sheets connected by hydrogen bonds run perpendicular to
the helical axis (Choi et al., 2008; Govaerts et al., 2004; Simkov-
sky and King, 2006). The repetition of b helix coils creates a
cylindrical hydrophobic core. The hydrophobic core of a b-helical
protein is characterized by buried stacks of similar side chains
(Choi et al., 2008; Jenkins and Pickersgill, 2001; Simkovsky
and King, 2006). While right-handed b helices (RbH) are generally
characterized by b strands connected by variable length turns
and loops (Heffron et al., 1998; Iengar et al., 2006; Jenkins and1014 Structure 17, 1014–1023, July 15, 2009 ª2009 Elsevier Ltd AllPickersgill, 2001), the right-handed b helix (LbH) is more rigid
and repetitive than the RbH variant (Choi et al., 2008; Iengar
et al., 2006; Jenkins and Pickersgill, 2001).
It has been proposed that misfolded proteins associated with
neurodegenerative diseases, such as prion disease, may adopt
an LbH fold (Govaerts et al., 2004; Langedijk et al., 2006; Stork
et al., 2005; Wille et al., 2002; Yang et al., 2005). Recent solid-
state nuclear magnetic resonance (NMR) studies of the fungal
HET-s prion protein showed that the misfolded amyloid confor-
mation may adopt an architecture that is structurally unrelated
to the native conformations, but that is similar to abhelix orb sole-
noid fold (Kajava and Steven, 2006; Wasmer et al., 2008). Hence,
it is plausible that mammalian prion proteins may also adopt
b-helical architecture in the misfolded state.
Misfolded amyloid proteins share common structural charac-
teristics, even when the native proteins are evolutionarily or
structurally unrelated. Amyloid fibrils are generally unbranched,
protease-resistant filaments with dominant b sheet structures
organized in a cross-b fashion in which the b strands run perpen-
dicular to the fibril axis (Jimenez et al., 2002; Murali and Jayaku-
mar, 2005; Serpell et al., 2007). Previous prion amyloid modeling
studies have converged on the b-helical architecture due to the
structural features that b-helical folds share with the unresolved
structure of longer chain amyloids. It has also been observed
that expression of the isolated b-helical domain of the RbH
protein, P22 tailspike protein, readily forms amyloid-like fibers
(Schuler et al., 1999). Therefore, understanding the role of amino
acid sequence in the folding of b helices may provide insight into
how misfolded proteins could form elongated b sheet structures.
E. coli UDP-N-acetylglucosamine acyltransferase (LpxA) was
the first example of a protein where an LbH is the predominant
secondary structure (Raetz and Roderick, 1995). LpxA is
a soluble, cytoplasmic protein that catalyzes the first step in the
biosynthesis of lipid A, the hydrophobic anchor of lipopolysac-
charides in gram-negative bacteria (Galloway and Raetz, 1990;
Wyckoff and Raetz, 1999). Lipid A is required for the growth of
E. coli and most other gram-negative bacteria and is also neces-
sary for maintaining the integrity of the outer membrane as
a barrier to toxic chemicals (Galloway and Raetz, 1990; Vaara,
1993). LpxA monomers are composed of a single b-helical
domain, capped at the C terminus with an a-helical domain;
they assemble into a homotrimer to form the active enzyme.rights reserved
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The Plasticity of the Left-Handed b HelixThe b-helical domain of LpxA contains approximately ten rungs
(or coils) with two loop excursions (Figure 1). Three repeats of
imperfect hexapeptide motifs ([LIV]-[GAED]-X2-[STAV]-X) make
up one rung of the b helix (Raetz and Roderick, 1995). Each
rung of the canonical b helix consists of three flat and untwisted
parallel b strands connected by either a one- or two-residue
turn or a long loop excursion region (Choi et al., 2008; Iengar
et al., 2006; Jenkins and Pickersgill, 2001; Kajava and Steven,
2006). Previous studies have shown defined residue distributions
at the various positions of the repeats: each b strand contains
small, uncharged residues (A, S, T, and C) and conserved, larger
hydrophobic residues (L, I, and V) that face the interior of the LbH
to create a hydrophobic core (Choi et al., 2008; Iengar et al., 2006;
Jenkins and Pickersgill, 2001; Kajava and Steven, 2006). These
constraints on the interior positions of theb strands are presumed
to have restricted sequence variation of the LbH proteins
throughout evolution (Parisi and Echave, 2001). The LbH fold is
highly regular and symmetrical with little variability in shape or
size over the length of the domain (Zheng et al., 2007). These
features also have led to the suggestion that LbH fold may be
used as a building block for nanotubular structures with applica-
tion in nanotechnology (Haspel et al., 2006, 2007; Zanuy et al.,
2007a; Zheng et al., 2007). With this interest, there have also
Figure 1. Monomeric and Trimeric Forms of the LbH Protein LpxA
(A) LpxA monomer structure (PDB ID: 1LXA) with labels at each rung. b-helical,
loop, and a-helical domains are shown. The ligand binding site is indicated by
the shaded circle. A tyrosine residue (Y184) at the bottom region of b-helical
domain is indicated.
(B) Cross-sectional view of the LpxA trimer. The ligand binding site is indicated
by the shaded circle.
(C) Cross-sectional view of the fourth rung of the LpxA b-helical domain. The
residues of the identified targeted region for the LpxA in vivo folding assay
(residues 51–62) are indicated.
(D) Cross-sectional view of the LpxA b-helical domain. The turn (T) and b sheet
(B) with the superscript ‘‘i’’ for a residue facing inside and ‘‘o’’ for a residue
facing outside.Structure 17, 10been recent studies to improve the stability of the bhelix structure
using conformationally constrained amino acids (Ballano et al.,
2008; Zanuy et al., 2007b). Despite growing interest in the LbH,
there has been little structural characterization of the LbH fold.
The accuracy of amyloid modeling studies using the LbH fold
has been limited by the relative absence of information pertaining
to the sequence requirements and structural features of this
relatively rare protein fold.
In the present study, we investigated the folding and stability of
the LpxA protein to examine the structural requirements of the LbH
fold by altering the sequence in the b-helical domain. We showed
that some nonhydrophobic residues could be tolerated at interior
positions of the b helix and that proline residues were important,
but not critical, in folding of thebhelix. We designeda recombinant
PrP-LpxA protein, in which a PrP fragment that is thought to be
essential for the conformational conversion was incorporated
into the b-helical domain of LpxA. Partial enzymatic activity was
observed, suggesting that the b-helical structure may be able to
accommodate a portion of the PrP sequence and, as a corollary,
that a PrP fragment may adopt LbH architecture.
RESULTS
In Vivo Functional Assay to Study Folding
of b Helices in LpxA
We developed a bioassay to evaluate the structural integrity of
LpxA using LpxA enzymatic activity. The E. coli strain SM101
is deficient in LpxA activity due to a G189S inactivating mutation
(glycine being the only residue allowed at position 189) in the
chromosomal gene (Galloway and Raetz, 1990; Odegaard
et al., 1997). This strain is defective in lipid A biosynthesis and
is temperature sensitive, showing no growth at 37C. At its
permissive growth temperature of 30C, SM101 displays hyper-
sensitivity to antibiotics such as novobiocin, rifampin, and eryth-
romycin that are normally excluded by the outer membrane
(Odegaard et al., 1997; Vuorio and Vaara, 1992). When SM101
is transformed with plasmids containing the wild-type lpxA
gene, normal growth is restored (Galloway and Raetz, 1990).
Therefore, enzymatic activity of any LpxA mutant can be directly
tested in a transformed SM101 strain exposed to various
concentrations of antibiotics.
We constructed pJC1 (His tag LpxA) and pJC2 (His tag LpxA
mutant containing a single tyrosine) plasmids as described in
the Experimental Procedures. pJC1 contained the gene for
wild-type LpxA, while pJC2 contained the gene for LpxA, where
all tyrosine residues except one were substituted with either
phenylalanine or histidine (Y66F, Y77F, Y219F, Y223F, and
Y243H). pJC2 had a relatively uncomplicated spectroscopic
signature, facilitating the characterization of the folded and
unfolded states. Negative control mutants were made by site-
directed mutagenesis at H125A and I86R of lpxA to generate
mutant pJC2-H125A and pJC2-I86R, respectively. H125 is an
important residue in the LpxA active site and its mutation almost
completely eliminates LpxA activity (Williams and Raetz, 2007;
Wyckoff and Raetz, 1999). The I86 residue is located in the fifth
rung of the b-helical domain in the hydrophobic core of a b helix
(Figure 1A). Based on our examination of the structure, a substi-
tution at I86 with a large, charged residue, such as arginine, was
targeted to promote improper folding or destabilization of the14–1023, July 15, 2009 ª2009 Elsevier Ltd All rights reserved 1015
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The Plasticity of the Left-Handed b Helixb-helical domain and thereby decrease LpxA activity of the
pJC2-I86R mutant. Hence, H125A (pJC2-H125A) was used as
a functional negative control mutant and I86R (pJC2-I86R) was
used as a structural negative control mutant. Both mutants
were used to test whether an LpxA functional assay could be
used as an in vivo folding assay for b-helical folding.
The SM101 (DE3) strain was transformed with pJC1, pJC2,
pJC2-H125A, and pJC2-I86R plasmids. Selected colonies of
each transformant and SM105 (isogenic wild-type strain of
SM101) were grown overnight, then transferred to 96 well plates
and grown in medium dosed ampicillin (50 mg/ml), streptomycin
(30 mg/ml), and novobiocin (0–256 mg/ml) at 30C. Novobiocin
was used to determine the antibiotic susceptibility of the
SM101 (DE3) strain once transformed with either wild-type
LpxA or the mutant plasmids. Bacterial growth was quantified
after 12 hr by measuring the optical density at 600 nm (OD600)
and expressed as a function of novobiocin concentration. Intro-
duction of the wild-type lpxA gene allowed E. coli containing the
lpxA2 mutation to grow under the same range of novobiocin
concentrations as SM105. As shown in Figure 2, the single tyro-
sine mutant construct, pJC2, also showed growth similar to wild-
type E. coli. Therefore, pJC2 was used as a wild-type LpxA
control in the present study. In contrast, pJC2-H125A and
pJC2-I86R showed significant reductions in growth and hyper-
sensitivity to novobiocin (minimum inhibitory concentration of
4 mg/ml versus 256 mg/ml for wild-type). This result was consis-
tent with previous studies of SM101 (Vuorio and Vaara, 1992).
Note that no isopropyl b-D-1-thiogalatopyranoside (IPTG) induc-
tion was required, as the basal protein expression was sufficient
to recover LpxA activity. Protein expression was verified by
western blot using an anti-his antibody (data not shown).
Mutagenesis Target Selection
We first aimed at identifying the best site to probe structural
requirements of the LbH in LpxA, i.e., where structural perturba-
tions will lead to a functional phenotype. Therefore we con-
ducted an arginine scan of the b-helical domain by site-directed
mutagenesis at hydrophobic residues in the b-helical core,
located in rungs 1–7 (Figure 1A). An in vivo folding assay with
Figure 2. LpxA In Vivo Folding Assay at 30C
LpxA folding assay (novobiocin: 0–256 mg/ml) showing bacterial growth of the
SM105 and SM101 E. coli strains and SM101 (DE3) E. coli strain transformed
with pJC1, pJC2, pJC2-H125A, and pJC2-I86R. Error bars are calculated from
three experimental trials.1016 Structure 17, 1014–1023, July 15, 2009 ª2009 Elsevier Ltd Allnovobiocin was conducted at 30C with the LpxA mutants I2R,
I20R, I38R, I56R, I86R, V111R, and V129R along with controls,
as described earlier (Figure 3A). The log LD50 (50% of the lethal
dose concentration) was calculated from the bacterial growth
curve plotted against the novobiocin concentration. Log LD50
was then plotted against the location of mutagenesis sites, refer-
enced by rung number (Figure 3B). The arginine scan of the
hydrophobic core of the b-helical domain showed that LpxA
can be fully or partially active, even with the disruption of up to
three rungs (I38R) of the b-helical domain. However, an arginine
mutation at I56 eliminated the activity of LpxA. Therefore, based
on our arginine scan and structural analysis of the active site, we
identified a region of rung 4 (residues 51–62) as an ideal target for
studying the folding and stability of the b-helical region.
Site-Directed Mutagenesis in the Hydrophobic
Core of the b-Helical Domain
In order to study the effect of nonhydrophobic residues in the
core of the b-helical region on LpxA folding, we conducted
Figure 3. LpxA In Vivo Folding Assay for Wild-Type LpxA and
Arginine LpxA Mutants at 30C
(A)LpxA foldingassay (novobiocin:0–256mg/ml) showingbacterial growth of the
SM101 (DE3) E. coli strain transformed with wild-type LpxA, LpxA-H125A, or
LpxA arginine mutants (I2R, I20R, I38R, I56R, I86R, V111R, and V129R). Hydro-
phobic residues at the Bi3 position were mutated in the LpxA arginine mutants.
(B) Average log (LD50) of each arginine LpxA mutant for three trials of the LpxA
in vivo folding assay, showing the large difference between the LpxA-I20R and
LpxA-I56R mutants.
Error bars are calculated from three experimental trials.rights reserved
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alanine, asparagine, glutamine, glycine, and arginine. SM101
(DE3) was transformed with the LpxA mutants and the in vivo
folding assay was performed at 30C. The assay was also
conducted at 37C in order to test whether SM101 (DE3) trans-
formed with LpxA mutants could restore E. coli growth and to
compare the effect of mutations on LpxA folding at a normal
growth temperature. Wild-type LpxA and negative control
(LpxA-H125A) mutants were also characterized in the in vivo
folding assay. At 30C, substitution of I56 with alanine did not
significantly affect the in vivo LpxA activity, but glycine, aspara-
gine, and glutamine mutations showed lower LpxA activity than
the wild-type. The arginine mutant was completely inactive (Fig-
ure 4A). At 37C, wild-type, alanine, asparagine, glutamine, and
glycine mutations showed similar levels of LpxA activity within
the range of standard deviation, but their LpxA activities at
37C were decreased by 2- to 4-fold compared to those at
30C. The arginine mutants showed complete loss of LpxA
activity at 37C (Figure 4B).
To assess these results at the level of protein expression, LpxA
mutants were individually overexpressed using IPTG induction at
30C. Soluble and insoluble fractions of the lysates were sepa-
rated by centrifugation and the samples were analyzed by elec-
trophoresis on an SDS polyacrylamide gel. As can be seen in
Figure 4C, wild-type LpxA, LpxA-H125A, and the alanine and
asparagine LpxA mutants were found mostly in the soluble
fractions. Weaker LpxA bands were observed from the soluble
fractions of lysates from the glutamine mutant bacteria. LpxA
from the glycine and arginine mutant bacteria were found mostly
in the insoluble fraction, indicating that the arginine mutation had
a detrimental effect on folding of the b helix. Although the expres-
sion level of soluble glycine LpxA mutant was lower than ex-
pected from the LpxA in vivo folding assay, protein expression
of the LpxA mutants was consistent overall with the LpxA
in vivo folding assay.
Proline Mutagenesis at the Turn Regions
of the b-Helical Domain
Surveys of known LbH structures indicate that proline residues
are restricted to defined positions, suggesting a possible role
in folding and stability (Choi et al., 2008). To investigate any
possible role for prolines in folding and stability, two proline
residues (P28 and P34) and four proline residues (P10, P28,
P34, and P183) at the T1 positions of the b-helical domain were
replaced with alanine using site-directed mutagenesis. These
were termed PtoA-2 and PtoA-4, respectively. The P182 residue,
which is located in the unusual turn position of Bo4, was excluded
from our scanning, due to its deleterious effect on LpxA folding
when mutated to glycine or alanine (data not shown). Results
from the in vivo folding assay showed that the activity of the
PtoA-4 mutant was lower than wild-type LpxA, but still greater
than the negative control, LpxA-H125A. The PtoA-2 mutant
showed greater activity than the PtoA-4 mutant (Figure 5A).
Unfolding and Refolding of LpxA Monitored
by Tyrosine Fluorescence
The thermodynamic stability of the wild-type and proline LpxA
mutant was probed by tyrosine fluorescence spectroscopy. We
used a modified LpxA background where all but a single tyrosineStructure 17, 10Figure 4. In Vivo Folding Assay for LpxA Mutants with Mutations in
the Hydrophobic Core
(A and B) LpxA folding assay, showing bacterial growth of the SM101 (DE3)
E. coli strain, transformed with LpxA containing one of the following mutations:
(A) At 30C, LpxA wild-type (LD50 = 34 ± 1.5 mg/ml), LpxA-H125A negative
control (LD50 = 0.42 ± 1.0 mg/ml), I56A (LD50 = 46 ± 2.3 mg/ml), I56N (LD50 =
22 ± 1.8 mg/ml), I56Q (LD50 = 12 ± 1.5 mg/ml), I56G (LD50 = 8.6 ± 1.7 mg/ml),
and I56R (LD50 = 0.27 ± 1.3 mg/ml); (B) At 37
C, LpxA wild-type (LD50 = 5.0 ±
1.6 mg/ml), LpxA-H125A negative control (LD50 = 0.034 ± 1.1 mg/ml), I56A
(LD50 = 3.9 ± 1.5 mg/ml), I56N (LD50 = 6.4 ± 1.9 mg/ml), I56Q (LD50 = 6.5 ±
1.8 mg/ml), I56G (LD50 = 5.2 ± 1.7 mg/ml), and I56R (LD50 = 0.034 ± 1.2 mg/ml).
(C) SDS polyacrylamide gel electrophoresis of soluble and insoluble fractions of
overexpressed LpxA cellular lysates is shown. Arrow indicates monomer bands
of LpxA and LpxA mutant proteins.
Error bars are calculated from three experimental trials.14–1023, July 15, 2009 ª2009 Elsevier Ltd All rights reserved 1017
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The Plasticity of the Left-Handed b HelixFigure 5. In Vivo Folding Assay and Spectroscopic Characterization
of Wild-Type LpxA and LpxA Proline Mutants
(A) The functional activity of LpxA mutants with two and four prolines replaced
by alanine residues in the b-helical domain PtoA-2 (LD50 = 13 ± 3.2 mg/ml) and
PtoA-4 (LD50 = 4.8 ± 1.7 mg/ml) at 30
C.
(B) Fluorescence emission spectra of LpxA in its native state (solid line) and in
its GdnHCl-denatured states (dotted line) were recorded in 100 mM sodium
phosphate (pH 7.5), containing 0–4 M GdnHCl.
(C) The folding and unfolding transition of wild-type LpxA and LpxA mutant
proteins. Transitions were measured using fluorescence (emission at
303 nm) after 30 min incubation. Uncorrected fluorescence emission spectra
were recorded with a Spex Fluoromax (excitation at 275 nm, spectral band-
width of 3 nm [excitation] and 3 nm [emission]). All spectra were recorded at
25C and are buffer-corrected. The protein concentrations were 100 mg/ml.
Error bars are calculated from three experimental trials.1018 Structure 17, 1014–1023, July 15, 2009 ª2009 Elsevier Ltd Allresidue (Y184) were replaced with phenylalanine or histidine in
order to simplify the fluorescence spectrum during folding and
unfolding. As Y184 is protected from the solvent by the C-terminal
domain, unfolding of the protein will lead to increased exposure of
Y184 that will translate into increased fluorescence intensity.
The mutant proteins were expressed and purified, as described
in the Experimental Procedures section. Upon excitation at
280 nm, maximal fluorescent emission was observed at 303 nm
(Figure 5B), which as expected increased in intensity upon addi-
tion of the denaturant, guanidine hydrochloride (GdnHCl), and
subsequent protein unfolding. To determine whether LpxA
unfolding induced by a chemical denaturant is reversible,
GdnHCl-induced folding and unfolding of LpxA was monitored
by measuring the tyrosine fluorescence spectra (Figure 5C).
Denaturation and renaturation curves were superimposable,
both with [GdnHCl]1/2 concentrations of 1.5 M. Only a single state
transition was observed and no trimer assembly was detected,
indicating that the change in fluorescence spectra reflects
changes of the monomer structure. To determine whether proline
mutations in the b-helical domain affect the thermodynamic
stability of LpxA, the unfolding transition of the PtoA-2 and
PtoA-4 mutants were monitored over a range of GdnHCl concen-
trations. As shown in Figure 5C, denaturation of the PtoA-2 and
PtoA-4 mutants occurred at lower denaturation concentrations
compared to the wild-type, with [GdnHCl]1/2 concentrations of
approximately 1.3 M and 1.1 M GdnHCl, respectively.
Residue Tolerance in the b-Helical Domain
A selected target region of the b-helical domain (residues 51–62)
was further studied by determining the amino acid residue toler-
ance at each position (Figures 1C and 1D). Based on our in vivo
and in vitro folding analysis of LpxA mutants, we selectedconcen-
trations of novobiocin (4–8 mg/ml) to measure viable LpxA activity
at 30C. We performed site-directed mutagenesis at all six b helix
positions (T1, T2, B
i
1, B
o
2, B
i
3, and B
o
4), introducing, one at a time,
residues that were not observed at these positions in known
structures of LbH. More specifically leucine, valine, and trypto-
phan were tested at position T1; isoleucine and valine at position
T2; glycine, asparagine, serine, and glutamine and methionine,
arginine, lysine, tryptophan, tyrosine, histidine, glutamate, aspar-
tate, and proline at positions Bi1 and B
i
3; and aspartate and
proline at Bo2 and B
o
4. LpxA mutants were transformed into
SM101 (DE3) and grown under novobiocin selection at 30C.
Table 1 summarizes the allowed and disallowed amino acid resi-
dues for each position of the b helix, as well as residues that have
been observed at each position, based on sequence analysis
(Choi et al., 2008). Any LpxA mutant strain that grew under the
selection criteria was considered a viable mutant and the amino
acid residue introduced in the mutant was categorized as
‘‘allowed.’’ While proline residues are restricted to only T1 and
T2 positions, as expected from the previous study (Choi et al.,
2008), glycine and hydrophilic residues, such as asparagine
and glutamine, that were not previously seen in the b-helical
core were shown to be tolerated at Bi1 and B
i
3 positions.
Inclusion of a PrP Fragment into the b-Helical
Domain of Recombinant LpxA
Our LpxA assay provides a simple way to test whether an
amyloid-forming peptide can adopt an LbH architecture. Basedrights reserved
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The Plasticity of the Left-Handed b HelixTable 1. Amino Acid Residue Tolerance of LpxA LbH Domain from the In Vivo LpxA Folding Assay
Type Position Knowna Allowed Not Allowed
T1 G52, R58 P, D, G, A, E, N, S, H, K, T, Y, M, F, R, Q, I, C L, V, W
T2 H53, D59 N, G, D, P, F, R, E, K, Q, H, S, Y, T, L, A, M, W, C I, V
Bi1 T54, N60 V, A, T, S, C, I, N, L, F G, Q, M R, K, W, Y, H, E, D, P
Bo2 K55, E61 V, T, I, S, E, Y, K, F, H, R, M, N, W, L, Q, A, G, C D P
Bi3 I56, I62 I, V, L, A, F, T, M, C G, N, Q, S R, K, W, Y, H, E, D, P
Bo4 G57, N51 G, E, A, D, H, V, N, S, I, K, R, M, T, L, Y, Q, C, F, W P
a Values were taken from the multiple sequence alignment of LpxA and other LbH proteins (Choi et al., 2008) and listed in order of occurrence
frequency. Amino acid residues tested and newly observed to be tolerated (Allowed) and not tolerated (Not Allowed) at each position of b helix domain
of LpxA. In vivo LpxA folding assay was conducted at 30C with 4–8 mg/ml of novobiocin as a selection concentration.on the observed residue tolerance at each position of the LpxA
b helix, we threaded fragments of mouse PrP (residues 104–
143) onto a target region of LpxA that we probed earlier to deter-
mine whether it is possible for this PrP sequence to fold into a
b helix. Combining previous studies (Choi et al., 2008; Govaerts
et al., 2004), and results from the present study (Table 1), the
sequence threading and modeling was conducted based on
the following criteria: proline residues are only allowed at the T1
and T2 positions, the B
i
1 position will only tolerate small residues,
while relatively large hydrophobic residues will be favored at
position Bi3. The restriction of glycine to some B
o
4 positions
was also considered. The threading result (Figure 6A) shows
a reasonable sequence alignment between mouse PrP sequence
(PrP residues 104–143) and the LpxA sequence (LpxA residues
22–59), with the exception of a short loop region (PrP residues
134–135). While glycine and alanine residues were placed at
several Bi1 and B
i
3 positions, proline residues were placed at T1
positions in order to meet the criteria. The modeling results also
show a reasonable structural alignment and packing of the inte-
riors of the b helix in PrP-LpxA models (see Figure S1 available
online). However, the substitutions with residues of small side
chains, such as glycine and alanine, resulted in loose packing
of the hydrophobic core, which may contribute to the destabiliza-
tion of the b helix structure.
A synthesized fragment of the prion gene was incorporated into
the lpxA gene following the sequence threading. LpxA monomer
structure with the target region for PrP fragment is shown in
Figure 6B. The prion fragment 104–143 was subcloned into the
corresponding region of lpxA in the pJC2 plasmid (replacing resi-
dues 22–29), and the resulting construct was then transformed
into SM101 (DE3) and tested for LpxA activity. In order to facilitate
proper assembly of the required trimeric LpxA structure, two resi-
dues involved in the trimeric interface of LpxA (F29 and H47) were
retained in PrP-LpxA. To ensure that the region into which the PrP
sequence was inserted is sensitive to the in vivo folding assay we
constructed the LpxA-V48R+T54R mutant. This mutant con-
tained arginine mutations in the region where the PrP sequence
was inserted. This first chimeric PrP-LpxA construct as well as
the LpxA-V48R+T54R mutant negative control were both inactive
in the in vivo assay (data not shown). Thus, a second chimeric
construct was prepared to include four more residues from
LpxA (i.e., G39 at Bo4, T42 at B
i
1, T54 at B
i
3, and I56 at B
i
3). Those
residues were selected since they were speculated to be highly
conserved due to the steric constraints on the particular region
of the LpxA b-helical domain. As shown in Figure 6C, this pseudoStructure 17, 10PrP-LpxA recombinant protein showed a substantial increase in
activity, albeit lower than that of the wild-type. Importantly, the
same construct with the additional V48R and T54R disrupting
mutations did not show any LpxA activity, indicating that the
enzyme is completely disrupted upon strong perturbation of the
b helix and therefore that the activity of the pseudo PrP-LpxA
protein isnot provided bya partlymisfolded enzyme. These results
suggest that the PrP 104-143 fragment may adopt a b-helical
architecture in the context of the chimera (see Discussion).
DISCUSSION
The LpxA assay developed here offers an indirect but simple way
to probe the relationship between sequence and structure of
LbH. The interest is 2-fold. First it provides an experimental tool
to test whether residue propensities and distributions, as identi-
fied by database surveys (Choi et al., 2008), fully define the LbH
or if the fold can accept more variations than those observed
in known structures and sequences. Second, considering the
proposed role of LbH architectures in amyloid formation, it
offers an experimental method to test whether amyloid-prone
sequences can adopt a b-helical structure.
Glycine and Hydrophilic Residues in the Hydrophobic
Core of the b Helix
Site-directed mutagenesis of the identified target region and
subsequent in vivo folding assays showed that the LpxA b helix
tolerates more residue types in the hydrophobic core than ex-
pected from database surveys. For example, sequence analysis
of LbH proteins has shown strong conservation of hydrophobic
residues, such as isoleucine, leucine, and valine at Bi3 (Choi
et al., 2008; Iengar et al., 2006). In contrast, the current in vivo
folding study has demonstrated that a single substitution with
hydrophilic residues, such as asparagine and glutamine, can still
be tolerated by the b helix. In the case of glycine at Bi3, some
activity is maintained, albeit decreased relative to the wild-type.
A decrease in the antibiotic resistance of the viable mutants
could either be due to a decrease in specific activity of the
LpxA mutant or to a decrease in the expression of the mutant.
An SDS-PAGE analysis of the expression profile of the various
LpxA mutants showed that a decrease in activity correlated
with an accumulation of the protein in the insoluble fraction.
This suggests that the destabilizing mutations affected the
folding efficiency, rather than specific activity (although a culmi-
nation of both effects cannot be excluded). This was particularly14–1023, July 15, 2009 ª2009 Elsevier Ltd All rights reserved 1019
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core, such as for the I56R mutant, where the protein is found
exclusively in insoluble inclusion bodies.
The results are overall consistent with an alanine site-directed
mutagenesis study of the RbH, P22 tailspike protein (Simkovsky
and King, 2006), such that the conserved hydrophobic residues
Figure 6. Threading the PrP Sequence onto the LpxA Protein and In
Vivo Folding Assay of the PrP-LpxA Recombinant Protein
(A) Threading of mouse PrP (residues 104–143) onto LpxA (residues 22–59).
PrP-LpxA is a chimeric protein where residues 22–59 of LpxA are replaced
by a modified PrP fragment (residues 104–143). Mutations are indicated by
lowercase letters. PrP residues (S134 and R135) that were not threaded
onto LpxA are indicated in italics. Residues at interior positions B1
i and B3
i
are indicated by underlined letters.
(B) Native PrP structure (PDB ID: 1QM0; residues 125–228). The PrP region
(residues 124–143) used in the LpxA threading is indicated by the shaded rect-
angle. LpxA monomer structure (PDB ID: 1LXA) with the target region for PrP
fragment insertion in the b-helical domain is indicated by the shaded rectangle.
(C) LpxA in vivo folding assay of PrP-LpxA (LD50 = 4.1 ± 1.3 mg/ml) and the
control mutant, LpxA-V48R+T54R (LD50 = 0.29 ± 1.2 mg/ml), at 30
C. Error
bars are calculated from three experimental trials.1020 Structure 17, 1014–1023, July 15, 2009 ª2009 Elsevier Ltd Allat the interior positions are important in folding of the b helix.
However, our results also revealed that LpxA can tolerate point
mutations with residues, such as glycine and glutamine at Bi3
positions, which were previously considered to be critical in
b-helical folding. The fact that glutamines and asparagines are
allowed at interior positions of LpxA is particularly interesting
knowing that the LbH fold has been proposed as a putative archi-
tecture for polyglutamine amyloid fibers (Chopra et al., 2008;
Govaerts et al., 2004). Indeed, such models require the presence
of glutamine side chains both on the outside and, importantly, in
the interior of the b helix.
The Effect of Proline Mutations on the Thermodynamic
Stability of the LbH Protein
Using the intrinsic tyrosine fluorescence spectrum we measured
the thermodynamic stability of LpxA ([GdnHCl]1/2 = 1.5 M
GdnHCl), which was in close agreement to the RbH domain of
the P22 tailspike protein reported by Schuler et al. (1999). In
order to accurately monitor protein denaturation and renatur-
ation using fluorescence, we have constructed the single tyro-
sine LpxA mutant, which contained a tyrosine residue at position
184. Y184 is located near the edge of the b helix and a helix
domain, away from the trimeric interface, and therefore the
decrease in fluorescence intensity observed most likely does
not reflect separation of the trimer, but rather monomer denatur-
ation. In addition, the shift in the denaturation curves observed
upon mutation of prolines, which are located further up the
b helix, indicates that we measured global protein denaturation
and not solely an increase of solvent exposure of Tyr 184.
As previously described (Choi et al., 2008), prolines in the
b-helical domain are mostly located at the top and bottom region
of the domain, leading us to speculate that they may play an
important role in the initiation or termination of b-helical folding.
Due to the unique structural properties, proline often plays a
key role in the protein structure. The effect of incorporating a con-
formationally constrained amino acid residue, such as proline
and proline analogues, into a peptide chain has been extensively
studied (Flores-Ortega et al., 2008). Our current result shows that
b-helical folding occurs without the proline residues, but the
LpxA activity is substantially reduced. Based on the LpxA
sequence and structure, the proline residues targeted for alanine
substitution were not located in the active site, nor are they ex-
pected to be involved in trimer formation. Therefore, the reduced
LpxA activity of the proline mutants can best be explained by the
decreased thermodynamic stability of the b helix, as indicated by
unfolding transitions monitored using tyrosine fluorescence
spectroscopy in the presence of a chemical denaturant. Proline
mutations of the b helix may also have an effect on the efficiency
of b-helical folding. However, in order to accurately determine
the folding efficiency of the b helix, folding kinetics of the wild-
type and other mutant proteins need to be investigated further.
PrP-LpxA Hybrid Recombinant Protein Supports
the b-Helical Model of PrPSc
Recent structural studies using microcrystals of amyloid forming
short peptides have suggested that fibrillar assemblies have
their origins in steric zippers, tightly packed b-structures of
both parallel and anti-parallel nature (Nelson et al., 2005; Sawaya
et al., 2007; Wiltzius et al., 2008). While the biological relevancerights reserved
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NMR and electron microscopy studies of Ab amyloid fibrils
have shown in-register parallel b structures (Petkova et al.,
2002; Sachse et al., 2008).
In the case of mammalian prions, a number of recent studies
suggest that the misfolded state may adopt a b-solenoid or
b-helical architecture (Govaerts et al., 2004; Langedijk et al.,
2006; Wasmer et al., 2008; Yang et al., 2005). The inherent
compactness and availability of accessible b faces to initiate
and sustain self-assembly make b-helical folds attractive candi-
dates for the structural unit of the prion amyloid fibril. Previous
modeling studies of PrPSc showed that the protein could adopt
two to four rungs of the b-helical fold (Govaerts et al., 2004; Lan-
gedijk et al., 2006; Yang et al., 2005). However, questions have
been raised about the validity of these b-helical models of PrPSc
because PrP contains sequence features that do not match
sequences of known b-helical proteins. While the insolubility of
PrPSc has limited structural studies to test the models by clas-
sical techniques, such as X-ray crystallography and NMR spec-
troscopy, the short fragments known to be prone to amyloid
formation (De Gioia et al., 1994; Forloni et al., 1993; Gasset
et al., 1992; Thellung et al., 2000) can be threaded and experi-
mentally tested using a recombinant LbH protein containing
a PrP-derived amyloidogenic fragment. This chimeric protein
was used to investigate the possibility of a b-helical structure
in the misfolded prion protein conformation.
Although results from the in vivo functional assay showed that
the PrP-LpxA recombinant protein had LpxA activity comparable
to other LpxA mutants, it may not provide sufficient evidence to
conclude that the PrP misfolds into a b helix. First, the PrP frag-
ment in the PrP-LpxA recombinant protein contained several
residues that were different from the wild-type prion. In the
PrP-LpxA recombinant protein, wild-type LpxA residues were
maintained for trimeric interface residues, a conserved glycine
residue at Bo4 position, and three interior residues at B
i
1 and
Bi3 positions for the following reasons. Residues involved in
the trimeric interaction may not be critical to b-helical folding,
but they may destabilize the formation of LpxA trimer, leading
to a false negative result for the in vivo folding assay. The Bo4
position can accommodate a range of different residues, but it
is often highly conserved as a glycine residue due to steric
constraints. Isoleucine and phenylalanine have been observed
at interior positions Bi1 and B
i
3. However, the packing of these
residues with other wild-type residues in the targeted region of
LpxA b-helical domain may not be compatible.
In addition, interpretation of the in vivo folding assay results for
PrP-LpxA is still somewhat problematic as the recombinant
protein did not exhibit wild-type-like LpxA activity. First, one
could suspect that LpxA could have accommodated a PrP-like
sequence in a non-b-helical-like structure (such as a loop) while
maintaining enzymatic activity. However, our arginine scanning
has demonstrated that structural perturbation in the third helical
rung strongly affects function while perturbation of the fourth
rung completely abrogated enzymatic activity. Our chimeric
construct integrated the PrP-like sequence in place of rung 2,
3, and 4 of LpxA with only moderate effect on enzymatic activity.
This suggests that the overall architecture had been preserved in
the vicinity of the fourth rung. In addition, accommodating a 40
residue segment into a non-b-helical structure should be quiteStructure 17, 1unfavorable to LpxA folding and assembly, especially consid-
ering the tightness of the trimerization interface of the enzyme.
A possibility would be that PrP-LpxA b-helical folding may occur,
but in a less stable form than in wild-type LpxA. Overexpression
of the PrP-LpxA recombinant protein was attempted under
several conditions, but insoluble aggregates are often formed
under the induced conditions, hampering biophysical character-
ization of the PrP-LpxA recombinant protein. Further studies are
necessary to explore expression conditions that will allow
examination of the structure and biophysical characteristics of
the PrP-LpxA recombinant protein and may lead to a better
understanding of PrP structure.
While the PrP sequence becomes relatively insoluble when it
adopts a b-rich structure, we believed that if the sequence could
be grafted successfully onto a sequence known to form a water
soluble trimeric LbH fold, we would create a useful tool for
studying PrP structure. As many features could limit the success
of the hybrid design, the negative result is of limited utility. For
example, the specific misfolded PrP structure could deviate
locally from that of known b-helical proteins, such as fungal
HET-s prion protein, or it could disrupt the solubility of the
chimeric construct. Therefore, it may be difficult to directly test
the full-lengthb-helical model of PrPSc on known solubleb-helical
proteins that facilitate spectroscopic characterization. For these
reasons, we focused on a b-rich segment of the prion protein
(PrP 103–143) and retained two LpxA residues that were involved
in the trimeric interface and four that played structural roles. We
believe that the ability of the hybrid to fold sufficiently to yield
enzymatic activity suggests that a central region of PrP may
adopt a b-helical structure. However, the tendency of this hybrid
to aggregate suggests that the intrinsic solubility of the b helix
with the PrP sequence is difficult to preserve.
EXPERIMENTAL PROCEDURES
Bacterial Strains
Bacterial strains SM105 (lpxA, Strepr) and SM101 (lpxA2, Strepr) (Galloway and
Raetz, 1990) were obtained from the E. coli Genetic Stock Center (Yale Univer-
sity, New Haven, Connecticut). SM101 (DE3) was prepared from SM101 using
the Lambda DE3 lysogenization kit (Novagen) and made electrocompetent for
transformation (Ausubel, 1987).
Site-Directed Mutagenesis
LpxA mutants were made by using the PCR-based QuikChange mutagenesis
procedure (Stratagene). Five tyrosine residues of LpxA were subjects to site-
directed mutagenesis in order to generate recombinant LpxA with a single
tyrosine. The resulting vector that contained the single tyrosine wild-type
LpxA clone, pJC2, encoded the full-length LpxA protein with the following
mutations: Y66F, Y77F, Y219F, Y223F, and Y243H. For all other LpxA mutants,
methylated pJC2 DNA was used as a template DNA for site-directed mutagen-
esis. A PCR reaction was carried out with forward and reverse primers, using
Pfu polymerase. The cycle was: 94C for 30 s, 55C for 1 min, and 62C for
10 min. This cycle was repeated 18 times. Plasmid DNA was purified using
QIAprep Spin MiniPrep kits (QIAGEN). DNA sequencing of an 800 bp region
containing the targeted codon confirmed mutant clones (Elim Biopharmaceut-
icals). Primers for mutagenesis and the PrP-LpxA recombinant gene were
custom made by Celtek Bioscience and Integrated DNA Technologies.
LpxA In Vivo Folding Assay
Previously prepared SM101 (DE3) electrocompetent cells were transformed
with pJC2 vectors, containing the single tyrosine wild-type and mutant LpxA
clones using a Gene Pulser Xcell Electroporator (Bio-Rad). Transformants
were plated on LB agar containing appropriate antibiotics (100 mg/ml ampicillin014–1023, July 15, 2009 ª2009 Elsevier Ltd All rights reserved 1021
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The Plasticity of the Left-Handed b Helixand 30 mg/ml streptomycin) and incubated at 30C. Colonies were picked and
inoculated in LB medium (100 mg/ml ampicillin and 30 mg/ml streptomycin) and
incubated for 12 hr at 30C. Two microliters of diluted overnight inoculums
were mixed in each well of 96 well plates, prepared with LB medium (100
mg/ml ampicillin, 30 mg/ml streptomycin, and 0–256 mg/ml novobiocin). The
96 well plates were incubated on a shaker at 30C for 12 hr and at 37C for
6 hr. The OD600 was recorded using a SpectraMax M5 microplate reader
(Molecular Device).
Protein Expression and Purification
LpxA and LpxA mutant proteins were expressed in SM101 (DE3) cells. LpxA
transformed cells were grown in LB medium (100 mg/ml ampicillin and
30 mg/ml streptomycin) at 15 to 30C until OD600 = 0.8. Cells were induced
with 0.5 mM of IPTG and grown for another 12 hr. Cell suspensions were
centrifuged and cell pellets were collected and lysed. Cell lysates were centri-
fuged at 15,000 rpm for 30 min to collect the soluble fraction. The pellets were
collected and resuspended in 8 M urea as insoluble fractions. For the in vitro
folding and unfolding study, the soluble proteins were purified using the
Ni-NTA purification system (QIAGEN) and size-exclusion chromatography.
The wild-type LpxA protein eluted as a 90 kDa protein, indicating that LpxA
mostly exists as a trimer in solution. Around 15 mg of purified protein was
obtained from 1 liter of bacterial culture. The collected protein samples were
separated on SDS polyacrylamide gels for verification of the LpxA monomer
(28 kDa).
In Vitro Folding and Unfolding (Tyrosine Fluorescence
Spectroscopy)
Folding transitions were measured in a Spex FluoroMax spectrofluorometer
(HORIBA Jobin Yvon, Inc.) with a thermostated cell holder using plastic fluo-
rescence cuvettes. The excitation wavelength was 280 nm and the emission
wavelengths were 280–400 nm. For unfolding transitions, cold buffer (100 mM
sodium phosphate [pH 7.5], containing 0.2 M NaCl and 1 mM EDTA) was first
mixed with 10 ml of concentrated protein solution (10 mg/ml). Then, a cold,
concentrated GdnHCl solution containing 100 mM sodium phosphate (pH
7.5), 0.2 M NaCl, and 1 mM EDTA was added (final volume 1 ml) to a final
protein concentration of 100 mg/ml. For refolding transitions, 4 M GdnHCl
solution was added and the samples were incubated for 30 min. Refolding
was initiated by rapid dilution with buffer containing 0.2 M NaCl and 1 mM
EDTA.
Sequence Threading and Molecular Modeling of PrP-LpxA
The models of PrP-LpxA were built on the template of LpxA N-terminal domain
(PDB ID code: 1LXA) by following the selected threading of mouse PrP
(residues 104–143) onto LpxA (residues 22–59). While the backbone chains
of LpxA were maintained, the side chains of the LpxA sequence (residues
22–59) were replaced with PrP sequence using Insight II software (Accelrys).
The side chain positions of the PrP-LpxA models were subsequently optimized
using SCWRL 3.1 (Canutescu et al., 2003). Models were further optimized
using two rounds of energy minimization using the GROMACS 3.1.3 package
(Van Der Spoel et al., 2005).
SUPPLEMENTAL DATA
Supplemental data include Supplemental Experimental Procedures and
one figure and can be found with this article online at http://www.cell.com/
structure/supplemental/S0969-2126(09)00226-3.
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